• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cordis S.M.A.R.T. stent still looking good at 3 years

Cordis S.M.A.R.T. stent still looking good at 3 years

January 24, 2014 By Chris Walker

Cordis releases 3-year stent trial data

Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. reported another year of results from its STROLL trial, which studied the durability and performance of the company’s S.M.A.R.T. vascular stent.

At the study’s final 3-year mark 78.5% patients did not need clinically driven target lesion revascularization, and the stent fracture rate remained low at 3.6% with all reported fractures labeled Type I, the least severe, according to a press release.

“We are very pleased that patients continue to feel better 3 years after treatment with the S.M.A.R.T. Stent," Cordis president Celine Martin said in prepared remarks. "We are continuing to build on the legacy of this exceptional platform with our next generation S.M.A.R.T. Flex Stent and look forward to delivering future innovations in self-expanding stents for patients suffering from peripheral artery disease."

The Bridgewater, N.J.-based medical device company makes less invasive treatment options for vascular disease. The S.M.A.R.T. stent is a smaller stent that can still minimize vessel prolapse while conducting the strength of blood flow.

The STROLL trial is a multi-center, non-randomized, single-arm prospective trial comparing the S.M.A.R.T. vascular stent systems against a published performance goal.

The new results come almost exactly 1 year to the day after Cordis reported its 2-year outcomes, at which time the company touted freedom from clinically driven target revascularization at 2 years in more than 80% of enrolled patients, nearly half of which were diabetic and nearly a quarter of which entered the trial with total occlusions.

Cordis is waiting to hear where stent pioneer Dr. Bruce Saffran appeal to the U.S. Supreme Court goes, in connection to the company’s recent $600 million patent infringement win. Saffran alleged that Cordis violated his patent with its Cypher drug-eluting stent, in a case he won. Nonetheless, last April the U.S. Court of Appeals for the Federal Circuit overturned the infringement ruling, on the grounds that the lower court’s claim construction was wrong.

Filed Under: News Well, Stents Tagged With: Clinical Trials, Cordis Corp., Johnson and Johnson

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy